The Power List 2026 is Live
We celebrate 60 inspiring individuals helping turn pharma’s boldest ideas into reality
Clinical Scorecard: The Power List 2026 is Live
At a Glance
| Category | Detail |
|---|
| Condition | Drug Discovery and Development |
| Key Mechanisms | Advancements in biomolecular understanding and manufacturing technologies. |
| Target Population | Physicians and patients seeking new therapies. |
| Care Setting | Pharmaceutical and biopharmaceutical development environments. |
Key Highlights
- Emerging drug discovery technologies are enhancing therapeutic options.
- Innovations include molecular glues, protein degraders, and cell therapies.
- Challenges include demonstrating value in a capital-constrained environment.
- The Power List features 60 individuals across three categories.
- Focus on creating manufacturability and access-by-design models.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with conditions addressed by new therapies.
Potential for effective therapies in various disease modalities.
Clinical Best Practices
- Encourage collaboration across different therapeutic modalities.
- Focus on manufacturability and access in therapy development.
Related Resources & Content
